Hemoglobinopathies Market Size, Share and Forecast 2026
The Hemoglobinopathies Market was worth $XX million in 2018 and is forecasted to reach $XX million by 2026, at a CAGR of XX% during the forecast period.
(EMAILWIRE.COM, September 16, 2019 ) Market Overview:
Hemoglobinopathy is a genetic disorder that causes abnormal production or aberration in the hemoglobin structure. Hemoglobinopathies are the most common type of Sickle Cell disease and are hereditary. The formation of the abnormal hemoglobin is observed due to structural defects in the hemoglobin molecule, diminished production of one of the two subunits of the hemoglobin molecule and abnormal associations of otherwise normal subunits. Hemoglobinopathies are formed due to defects in genes and anemia.
Market Dynamics:
The market is driven by rising cases of hemoglobin disorders such as sickle cell disease, thalassemia, Hb C, and Hb E, increase in R&D activities to develop new therapeutics, increase in awareness program by government and robust pipeline. Insufficient healthcare infrastructure, no permanent cure, and lack of skilled professionals to interpret the complex data are going to restrain the market in the forecast period.
Market Segmentation:
By Type
• Thalassemia
• Sickle Cell Disease
• Hb Variants Diseases
By Diagnosis Test Type
• Genetic Testing
• High Performance Liquid Chromatography
• Hemoglobin Electrophoresis
• Molecular Methods
• Polymerase Chain Reaction (PCR)
• Restriction Fragment Length Polymorphism (RFLP)
• DNA Sequencing
By Therapy
• Blood Transfusion
• Bone Marrow Transplant
• Iron Chelation Therapy
• Folic Acid Supplements
Geographical Analysis:
By Geography, the market is segmented into:
• North America
• Europe
• South America
• Asia Pacific
• The Middle East and Africa
Competitive Analysis:
Key Players:
• Gamida Cell *
• Alnylam Pharmaceuticals
• Sanofi
• Sangamo Therapeutics Inc.
• Global Blood Therapeutics
• Bluebird bio Inc.
• Others
View full report: https://www.datamintelligence.com/research-report/hemoglobinopathies-market
Download free sample: https://www.datamintelligence.com/download-sample/hemoglobinopathies-market
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
Hemoglobinopathy is a genetic disorder that causes abnormal production or aberration in the hemoglobin structure. Hemoglobinopathies are the most common type of Sickle Cell disease and are hereditary. The formation of the abnormal hemoglobin is observed due to structural defects in the hemoglobin molecule, diminished production of one of the two subunits of the hemoglobin molecule and abnormal associations of otherwise normal subunits. Hemoglobinopathies are formed due to defects in genes and anemia.
Market Dynamics:
The market is driven by rising cases of hemoglobin disorders such as sickle cell disease, thalassemia, Hb C, and Hb E, increase in R&D activities to develop new therapeutics, increase in awareness program by government and robust pipeline. Insufficient healthcare infrastructure, no permanent cure, and lack of skilled professionals to interpret the complex data are going to restrain the market in the forecast period.
Market Segmentation:
By Type
• Thalassemia
• Sickle Cell Disease
• Hb Variants Diseases
By Diagnosis Test Type
• Genetic Testing
• High Performance Liquid Chromatography
• Hemoglobin Electrophoresis
• Molecular Methods
• Polymerase Chain Reaction (PCR)
• Restriction Fragment Length Polymorphism (RFLP)
• DNA Sequencing
By Therapy
• Blood Transfusion
• Bone Marrow Transplant
• Iron Chelation Therapy
• Folic Acid Supplements
Geographical Analysis:
By Geography, the market is segmented into:
• North America
• Europe
• South America
• Asia Pacific
• The Middle East and Africa
Competitive Analysis:
Key Players:
• Gamida Cell *
• Alnylam Pharmaceuticals
• Sanofi
• Sangamo Therapeutics Inc.
• Global Blood Therapeutics
• Bluebird bio Inc.
• Others
View full report: https://www.datamintelligence.com/research-report/hemoglobinopathies-market
Download free sample: https://www.datamintelligence.com/download-sample/hemoglobinopathies-market
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
Contact Information:
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results